Articles On Compumedics (ASX:CMP)

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

Integral Diagnostics and Medadvisor have new CEOs after the latest round of changes at the top Mayne’s refrain: let the Takeovers Panel decide It’s a case of the MEGnificent Five as Compumedics sells another brain-scanning device in China...

Compumedics (ASX:CMP) has inked the fifth order with a customer worth $5 million for its magnetoencephalography-based (MEG) brain scanner tech, called Orion Lifespan, to a university in Beijing, bringing total sales thus far to $25 million...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

Compumedics (ASX:CMP) has completed a $2.15 million placement to accelerate the commercialisation of its Somfit D sleep diagnostic device, following early U.S. Food and Drug Administration approval. Listen to the HotCopper podcast for in...

Aussie and Asian markets fall after Trump threatens more tariffs on China Gold and silver reach new record highs with strong demand for safe haven assets Materials sector slips into red in afternoon trade as tech leads laggards   The Auss...

Catapult Group is buying a German soccer analytics and talent scouting firm for $140 million PainChek signs its maiden US aged-care client Biotechs flock to the funding well – with more raisings to come   A global leader in athlete health...

Compumedics (ASX:CMP) has seen record sales orders and continued momentum across its core and emerging platforms, including strong growth in its SaaS-based sleep diagnostics business and expansion into global neuroimaging markets. Listen...

For veteran brain and health diagnostic outfit Compumedics (ASX:CMP), it’s time to deploy what founder, CEO and chair Dr David Burton dubs the “bunker busters”. The hitherto impenetrable target is the US capital market, which the Melbourne-...

Compumedics (ASX:CPM), a world leader in sleep and neuro diagnostics, is growing as a company, which isn’t surprising when considering the growing prevalence of modern health conditions affecting neuro behaviours like sleep.  For more th...

While sector conditions are improving, investors still can pick up marked-down, revenue-generating biotechs Dozens of offshore life science plays trade at below net asset backing, but the discounts on the ASX aren’t quite so harsh Investor...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

Compumedics shares surge up to 13% after FDA approval of its Somfit D device Don’t miss out on an options windfall, warns 4D Medical Amplia doses first patient in follow-on pancreatic cancer trial   Brain diagnosis house Compumedics (ASX...

Compumedics secures two lucrative sales for its Somfit sleep device with combined revenues approaching $2 million Sales to a leading CRO in US and a Finnish pharmaceutical company support strategy to expand in adjacent markets East Coast R...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

A trade deal between the EU and US has staved off the worst tariff fears Telecoms led gains alongside financials and healthcare Banking stocks end bearish run, gaining 0.81pc   ASX holds its nerve After a shaky start to trade this morning...

Compumedics signs two lucrative four-year distribution deals in Asia strengthening footprint in region An agreement worth $20 million signed with sleep diagnostics distributor in Northern China Second agreement, worth $4.4 million, inked w...

Compumedics (ASX: CMP) has marked a strategic turning point in its development after posting record sales and profitable growth for the 2025 financial year. The company racked up $63.4 million in sales for the period, representing a growth...

ASX walks tightrope to slide just 9.7 points All Ords gold sub-index climbs 1.87pc Iron ore prices boost big cap mining stocks ASX slides on renewed tariff threats The ASX 200 finished the day down 0.11%, having plunged a good 20 points i...

Compumedics achieves record revenue of $51 million and sales orders of $63.4 million in FY25 Company returns to profitability, with EBITDA of ~$3 million and sleep and neurology segment orders up 439% Compumedics reaffirms FY26 guidance of...

Imugene reports two more ‘complete responders’ in its cell therapy trial Clever Culture Systems shares surge 17% on deal with Big Pharma Novo Nordisk  Compumedics shares vault 24% after full-year update   Imugene (ASX:IMU) will forge ahea...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am, once trading kicks off in earn...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

China Brain Project rolls out neuro-AI push Compumedics dual-helmet MEG lights up Tianjin labs ASX health stocks surge deeper into China   A few years back, China kicked off what might be one of the most ambitious science missions you’ve...

Two equity research firms endorse Compumedics and see upside to share price Recent FDA clearance for its next-generation home sleep tests set to open lucrative new market Neuroscan Orion LifeSpan magnetoencephalography system also provides...

Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath. In this episode Nadine chats to Gordon Haid, the Global Neuro-Imaging Business Director of Compumedics (ASX:CMP), a medical...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Compumedics wins new Somfit sale worth about $1 million to one of the world’s leading pharmaceutical contract research organisations Somfit will be used in a series of pharmaceutical clinical trials to assess impact on sleep of a new drug...

Highlights: ASX 200 opens lower, ending a recent winning streak amid softer commodity sentiment Gold and copper prices decline while aluminium edges higher in global trade Key activity in small and mid-cap sectors with devel...

Compumedics’ MEG unit can scan adult and kid’s heads at the same time – a technically tricky task Microba’s comprehensive gut testing reveals all is not well in the tummy region Trump’s drug pricing blitz should be “immaterial”, says Telix...

Compumedics Neuroscan Orion LifeSpan magnetoencephalography system records brain activity in children First time a single magnetoencephalography system has delivered high quality scans from both children and adults Breakthrough at world’s...

ASX medtechs are taking brain diagnostics beyond the hospital or clinical settings to the front lines of care EMVision’s First Responder portable brain scanning technology aims to speed up stroke detection for better patient outcomes Cogst...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Sandoz backs Avecho in $3m CBD sleep capsule play Neurotech also eyes sleep as secondary endpoint in CBD trials The hot sleep space is led by companies like Resmed and Compumedics   Melbourne-based biotech Avecho has just pulled off a big...

Compumedics founder David Burton says brain imaging can rival the magnetic resonance imaging (MRI) market Having recently gained FDA approval, the company is eyeing the emerging US home sleep testing sector Compumedics will appoint an inde...

Donald Trump exempts “pharmaceuticals” from his tariff blitz ASX device makers mull their US manufacturing plans as Ansell shares plunge Race and Imugene progress their early-stage oncology trials   Liberation Day has spared the pharmaceu...

In the arvo session, the ASX held on to early gains… by a thread Nervy investor/trader eyes now await updates from the US on yet more inflation data and tariff announcements Amid the turmoil, wouldn’t you know it, gold stole the show   Af...

Compumedics receives new order for Neuroscan Orion LifeSpan MEG system in China The order will bring installation of systems in China to four with total revenue of about $20 million Compumedics expects to ship and install the new system at...

ASX up as it notches one of best weeks of the year Woolies, Coles win big, miners hit hard on Trump’s exec order Greenhy2 soars 300pc after signing storage tech deal with H2Core   The ASX 200 had a rollercoaster day, but it ended Friday’s...

Brain research technologies specialist Compumedics (ASX: CMP) has reached $20 million in sales for its magnetoencephalography (MEG) system in China. The latest $5.7m contract from Hangzhou Normal University follows the successful installati...

TBI awareness month highlights need for better care ASX companies roll out devices to tackle TBI head-on From portable scanners to life-changing tech, TBI solutions are evolving   March is Traumatic Brain Injury (TBI) Awareness Month, a...

Nanosonics shares pop 13% after getting the FDA’s nod for its next-gen sterilising device Imricor completes $70 million raising Bell Potter says Polynovo shares should be worth more than double what they are   It’s reassuring to know the...

  Compumedics receives US FDA clearance for its Falcon home sleep testing solution Falcon to complement Compumedics Somfit technology platform, which is gaining traction in US Compumedics said home sleep testing market in US represents pot...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead. In this edition, Fraser Palamara looks at Compumedics (ASX:CMP), a company that diagnoses sle...

Melbourne-based medical device company Compumedics (ASX: CMP) has chalked up record orders totalling $32.8 million for the first half of FY25, almost $2 million more than forecast just three weeks ago, as the group’s US business continues t...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

Toothy white smiles as SDI reports strong initial sales of its company-making Stela fillings  Trivarx awaits FDA key decision on its trial design  Compumedics completes its biggest deal to date   Dental products stalwart SDI (ASX:SDI) rep...